GLORIA PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 60.2523 million yuan, a year-on-year increase of 15.24%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, GLORIA PHARMA released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 551 million yuan, a year-on-year decrease of 7.06%. The net profit attributable to shareholders of the listed company was 60.2523 million yuan, a year-on-year increase of 15.24%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 49.733 million yuan, a year-on-year increase of 54.74%
According to the Zhitong Finance APP, GLORIA PHARMA (002437.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 551 million yuan, a year-on-year decrease of 7.06%. The net profit attributable to shareholders of the listed company was 60.2523 million yuan, a year-on-year increase of 15.24%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 49.733 million yuan, a year-on-year increase of 54.74%